PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025

2017-05-30
Price :
Published : May-2017
No. of Pages : 317

PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025

Summary

COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough, and increased mucous production, worsen over time.

Chronic obstructive pulmonary disease (COPD) treatment originated from asthma treatment and exacerbating individuals benefited from the ICS/LABA drug class, leading to even higher sales for GSK’s Advair and AstraZeneca’s Symbicort. Boehringer Ingelheim’s Spiriva (tiotropium) was introduced in the COPD treatment management in 2002, and has since become a global blockbuster as a COPD-targeted therapy with a remarkable impact on patients’ quality of life.

It estimated that the 2015 COPD drug sales to be US$9.9 Billion across the eight major pharmaceutical markets 8MM covered in this report. By the end of the forecast period in 2025, sales will increase to US$14.1 Billion at a Compound Annual Growth Rate (CAGR) of 3.7%, which includes seven pipeline therapies.

COPD is a market with a substantial number of unattained unmet needs, including stakeholders’ recognition of symptoms, treatment that reverses the progression of COPD, and identification of biomarkers. This is not very common for a disease with such an established treatment management and numerous marketed drugs. This is because of the multifactorial causes of the disease combined with a low diagnosis rate across the 8MM. COPD is called the ‘smoker’s disease’ since many of the afflicted individuals are or have been smokers for an extended period of their lives.

Boehringer Ingelheim was the market leader in 2015 with sales of US$3.2 Billion between Striverdi Respimat, Spiriva HandiHaler and Respimat, and Spiolto Respimat across the 8MM. GSK lagged behind with sales of US$2.4 Billion across the LABA, LAMA, LABA/LAMA, and ICS/LABA drug classes, followed by AstraZeneca with sales of US$1.5 Billion between Tudorza Pressair, Duaklir Genuair, and Symbicort. Novartis fell behind with sales of US$443.3 million without a blockbuster therapy in the COPD market.

The report “PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025”, Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In depth, this report provides the following analysis –
– Topline COPD market revenue from 2015-2025. ACOT and major pipeline product sales in this forecast period are included.
– Presents the key metrics for chronic obstructive pulmonary disease (COPD) in the eight major pharmaceutical markets (8MM) – the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Australia-during the forecast period from 2015-2025.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sunovion.

Scope

– Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
– Topline COPD market revenue from 2015-2025. ACOT and major pipeline product sales in this forecast period are included.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global COPD therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019" provides an overview of Clostridium difficile Infections (Clostridium difficile Associated Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium difficile Infections (Clostridium difficile Associated Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and s......
$2500

Cystinosis Global Clinical Trials Review, H1, 2019

Cystinosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cystinosis Global Clinical Trials Review, H1, 2019" provides an overview of Cystinosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystinosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are ......
$2500

Community-Acquired Infections Global Clinical Trials Review, H1, 2019

Community-Acquired Infections Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Community-Acquired Infections Global Clinical Trials Review, H1, 2019" provides an overview of Community-Acquired Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprie......
$2500

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2019

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global......
$2500

Corneal Neovascularization Global Clinical Trials Review, H1, 2019

Corneal Neovascularization Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Corneal Neovascularization Global Clinical Trials Review, H1, 2019" provides an overview of Corneal Neovascularization clinical trials scenario. This report provides top line data relating to the clinical trials on Corneal Neovascularization. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Clostridium Infections Global Clinical Trials Review, H1, 2019

Clostridium Infections Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Clostridium Infections Global Clinical Trials Review, H1, 2019" provides an overview of Clostridium Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy